Cargando…
Nrf2 activators as potential modulators of injury in human kidney cells
Cisplatin is a chemotherapeutic agent used in the treatment of solid tumors, with clinical use often complicated by kidney toxicity. Nuclear factor (erythroid-derived-2)-like 2 (Nrf2) is a transcription factor involved in kidney protectant effects. The purpose of this study was to determine whether...
Autores principales: | Atilano-Roque, Amandla, Wen, Xia, Aleksunes, Lauren M., Joy, Melanie S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615789/ https://www.ncbi.nlm.nih.gov/pubmed/28959534 http://dx.doi.org/10.1016/j.toxrep.2016.01.006 |
Ejemplares similares
-
Identification of Novel Biomarkers for Predicting Kidney Injury Due to Drugs Using “Omic” Strategies
por: Awdishu, Linda, et al.
Publicado: (2020) -
Time-dependent changes in kidney injury biomarkers in patients receiving multiple cycles of cisplatin chemotherapy
por: George, Blessy, et al.
Publicado: (2020) -
In Vitro Inhibition of Renal OCT2 and MATE1 Secretion by Antiemetic Drugs
por: George, Blessy, et al.
Publicado: (2021) -
Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin
por: Chang, Cara, et al.
Publicado: (2017) -
Effect of Redox Modulating NRF2 Activators on Chronic Kidney Disease
por: Choi, Bo-hyun, et al.
Publicado: (2014)